Abingworth's Bet On Lombard: Best Of Both Worlds For VCs
Executive Summary
As venture investing in medical devices continues to split between early- and late-stage deals, investors increasingly face a choice: early-stage deals, where valuations are low, but risk is high and timelines are generally long; and late-stage opportunities, where risk is lower and timelines shorter, but the valuations are much higher. What if you could find an opportunity with the timelines and risk profile of a late-stage deal, at the valuation of an early-stage deal? That's what investors at Abingworth believe they've found in Lombard Medical Technologies PLC, a company with a novel approach to endovascular abdominal aortic aneurysm repair.